<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=US-ASCII">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-13">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Thu Feb 13 12:53:27 2003" -->
<!-- isoreceived="20030213195327" -->
<!-- sent="Thu, 13 Feb 2003 15:03:21 -0500" -->
<!-- isosent="20030213200321" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLIEOACJAA.rms2g@virginia.edu" -->
<!-- charset="US-ASCII" -->
<!-- inreplyto="015f01c2d0de$93d8a0c0$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Thu Feb 13 2003 - 13:03:21 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2665.html">EvMick@aol.com: "Media Bias"</a>
<li><strong>In reply to:</strong> <a href="2430.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2666">[ date ]</a>
<a href="index.html#2666">[ thread ]</a>
<a href="subject.html#2666">[ subject ]</a>
<a href="author.html#2666">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<em>&gt; Here is yet more evidence that selegiline (deprenyl) may increase
</em><br>
<em>&gt; life-expectancy in humans.
</em><br>
<em>&gt;
</em><br>
<em>&gt; In this study, treated animals enjoyed a 34% increase in life span.
</em><br>
<p>### The study provides evidence that rats on selegiline live longer. Whether
<br>
the same applies to humans, is a matter of conjecture, which is why I agree
<br>
with your use of &quot;may&quot;, as in &quot;maybe yes, maybe not&quot;.
<br>
<p>Rafal
<br>
<p><em>&gt;
</em><br>
<em>&gt; ABSTRACT:
</em><br>
<em>&gt; Deprenyl increases the life span as well as activities of superoxide
</em><br>
<em>&gt; dismutase and catalase but not of glutathione peroxidase in selective
</em><br>
<em>&gt; brain regions in Fischer rats
</em><br>
<em>&gt;
</em><br>
<em>&gt; Kitani K, Kanai S, Carrillo MC, Ivy GO
</em><br>
<em>&gt;
</em><br>
<em>&gt; Radioisotope Research Institute,
</em><br>
<em>&gt; Faculty of Medicine,
</em><br>
<em>&gt; University of Tokyo, Japan.
</em><br>
<em>&gt; Ann N Y Acad Sci 1994 Jun 30; 717:60-71
</em><br>
<em>&gt;
</em><br>
<em>&gt; ABSTRACT
</em><br>
<em>&gt;
</em><br>
<em>&gt; (-)Deprenyl, a MAO-B inhibitor that is also known to be effective for
</em><br>
<em>&gt; symptoms of Parkinson's disease, when injected subcutaneously (sc) in
</em><br>
<em>&gt; male Fischer-344 rats at a dose of 0.5 mg/kg per day (3 times a week)
</em><br>
<em>&gt; from 18 months of age, significantly increased the remaining life
</em><br>
<em>&gt; expectancy. The average life span after 24 months was 34% greater in
</em><br>
<em>&gt; treated rats than in saline-treated control animals. Furthermore, a
</em><br>
<em>&gt; short-term (3 wk) continuous sc infusion of deprenyl significantly
</em><br>
<em>&gt; increased activities of superoxide dismutase and catalase but not of
</em><br>
<em>&gt; glutathione peroxidase in selective brain regions such as s. nigra,
</em><br>
<em>&gt; striatum, and cerebral cortex, but not in hippocampus or cerebellum,
</em><br>
<em>&gt; or the liver. The optimal dose for increasing these activities,
</em><br>
<em>&gt; however, differed greatly depending on the sex and age of animals,
</em><br>
<em>&gt; with a 10-fold lower value for young female than male rats.
</em><br>
<em>&gt; Interestingly, aging caused an increase and a decrease in the optimal
</em><br>
<em>&gt; dose in female and male rats, respectively.  In addition, treatment
</em><br>
<em>&gt; for a longer term tended to reduce the optimal dosage in the same
</em><br>
<em>&gt; animal group. The results clearly demonstrate that deprenyl increases
</em><br>
<em>&gt; antioxidant enzyme activities in selective brain regions.  If this
</em><br>
<em>&gt; effect of deprenyl is causally related to its life-prolonging effect,
</em><br>
<em>&gt; the dosage to be used for any life span study would be a critical
</em><br>
<em>&gt; factor, with the dosage differing widely depending on sex, age of
</em><br>
<em>&gt; animal, and mode and duration of drug administration.
</em><br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Previous message:</strong> <a href="2665.html">EvMick@aol.com: "Media Bias"</a>
<li><strong>In reply to:</strong> <a href="2430.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2667.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2666">[ date ]</a>
<a href="index.html#2666">[ thread ]</a>
<a href="subject.html#2666">[ subject ]</a>
<a href="author.html#2666">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Thu Feb 13 2003 - 12:55:36 MST
</em></small></p>
</body>
</html>
